Docetaxel combined with CV787 (PSA+ conditionally replicating adenovirus) synergistically reduced prostate cancer in a xenograft mouse model, where the combinatorial treatment increased the expression of p53 27. This evidence concerns the gene TP53 and prostate carcinoma.